Every AXLRx Type 2 Diabetes report, across 6 report types. Each is scoped to your asset and verified to a live source.
Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.
38.4M US adults, an 8.7M undiagnosed pool, and complication burden driving GLP-1 and SGLT2 organ-protection strategy.
Type 2 Diabetes is IRA ground zero: three orals negotiated for 2026, semaglutide at $274 for 2027, and the class price anchor reset.
Tirzepatide's 41% new-GLP-1 share and semaglutide's SELECT label set the efficacy and label bar. A new entrant must clear both while an IRA-reset price anchor is closing in behind it.
Two IRA negotiation cycles have now cut across the T2D formulary: Januvia down 79% to $113, Jardiance down 66% to $197, Farxiga down 68% to $178 from January 2026, and semaglutide down 71% to $274 with Janumet and Tradjenta added for 2027.
IQVIA puts the 2023 US T2D drug market at $22B top-down. Triangulated bottom-up against 29.7M diagnosed patients out of 38.4M with the disease, the two methods converge, but per-class revenue split remains an open gap this model flags rather than invents.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, Launch Readiness, Pricing Strategy Model, and Market Sizing Model for Type 2 Diabetes. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Type 2 Diabetes coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Type 2 Diabetes reports were updated July 2026.